Christopher Christian, MD
Psychiatry · Milwaukee, WINPI 1821261272
Payments from drug & device makers
Across 47 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$170
- Johnson & Johnson$152
- Otsuka America Pharmaceutical, Inc.$131
- Indivior Inc.$96
- AbbVie$80
- E.r. Squibb & Sons, L.L.C.$57
- plus $235 from 8 others
What the payments were for
- Food & beverage$921100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 8 | $170 |
| Johnson & Johnson | 10 | $152 |
| Otsuka America Pharmaceutical, Inc. | 6 | $131 |
| Indivior Inc. | 4 | $96 |
| AbbVie(2 entities) | 4 | $80 |
| E.r. Squibb & Sons, L.L.C. | 2 | $57 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $49 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| Braeburn Inc. | 2 | $38 |
| Supernus Pharmaceuticals, Inc. | 2 | $38 |
| Tris Pharma Inc | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Corium, LLC | 2 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
How this compares
$921 in reported general payments places this provider in the 80th percentile of 543 psychiatry providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 18 | $163,393 |
| VraylarCariprazine Hcl | 103 | $157,081 |
| IngrezzaValbenazine Tosylate | 18 | $153,829 |
| SublocadeBuprenorphine | 32 | $69,262 |
| Invega SustennaPaliperidone Palmitate | 13 | $46,542 |
| CaplytaLumateperone Tosylate | 26 | $45,188 |
| RexultiBrexpiprazole | 25 | $38,795 |
| TrintellixVortioxetine Hydrobromide | 76 | $37,266 |
| VyvanseLisdexamfetamine Dimesylate | 44 | $24,355 |
| Clozapine | 288 | $17,139 |
| Risperdal ConstaRisperidone Microspheres | 26 | $16,073 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 34 | $14,260 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $13,435 |
| Adderall XrDextroamphetamine/Amphetamine | 17 | $9,739 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 42 | $7,836 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Risperdal Consta, Concerta | $152 | $232,05971 claims |
| AbbVieVraylar | $80 | $157,081103 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $14 | $153,82918 claims |
| Indivior Inc.Sublocade, Suboxone | $96 | $83,52266 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $17 | $61,621120 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $49 | $45,18826 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $131 | $38,79525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 543 psychiatry providers in Wisconsin.
Other psychiatry in Milwaukee
- Thomas IlicMilwaukee$324K
- Jay WinstonMilwaukee$238K
- Joseph BurgarinoMilwaukee$111K
- Jacob BehrensMilwaukee$94K
- Selahattin KurterMilwaukee$17K
- Harold HarschMilwaukee$8K
- Ajay SehgalMilwaukee$7K
- James WinstonMilwaukee$7K
- Edgar JacksonMilwaukee$5K
- Ali ArtarMilwaukee$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.